Alzheimer’s disease has long baffled scientists. Treatments remain limited, and our understanding of the brain’s earliest changes remains incomplete. However, a new study led by Dr. Stuart Lipton at Scripps Research may be about to change that. Published in the journal Antioxidants, the research uses an innovative single-cell technique that links electrical activity to protein expression, and the team has already identified 50 molecular culprits that might be driving the early stages of Alzheimer’s.
This study didn’t just pinpoint problems—it also offered hope. The researchers homed in on a compound found naturally in herbs like rosemary and sage. Known as carnosic acid, it seems capable of calming the overactive brain cells seen in Alzheimer’s, offering a potential starting point for a new kind of treatment.
Studying a single brain cell, from firing to function
The real leap forward here was technical. Lipton’s team combined electrophysiology—a method of listening to the electrical signals in brain cells—with proteomics, which reveals the proteins those cells produce. Together, this “patch-clamp/proteomics” method gave them a complete profile of a single neuron, both how it behaves and what it’s made of.
In Alzheimer’s, many neurons become hyperexcitable—they fire more often than they should, causing damage over time. Using human-derived neurons with a genetic predisposition to Alzheimer’s, the researchers confirmed this overactivity and then matched it with the specific proteins present in each cell. The result was a map of around 2,250 proteins, with 50 standing out as especially relevant.
As Lipton told Scripps, “It’s been difficult to get at what’s happening inside individual neurons in Alzheimer’s… but now we can connect the dots between how a cell behaves and what molecules are involved.” That connection is vital, because it helps researchers understand why neurons are malfunctioning—not just that they are.
From rosemary to the lab: The promise of carnosic acid
Perhaps the most intriguing part of this discovery is the potential of carnosic acid. The compound is found in high concentrations in rosemary and sage, herbs long associated with memory and cognition in traditional medicine. Now, modern science is catching up. The team found that carnosic acid can help regulate electrical activity in hyperexcitable neurons, possibly restoring balance.
This could have major implications. Instead of targeting Alzheimer’s at its late stages—after plaques and tangles have already caused damage—drugs derived from carnosic acid might offer a way to intervene earlier, before these symptoms appear. Carnosic acid’s known anti-inflammatory and antioxidant properties also make it a compelling compound for further development.
While it’s far too early to suggest eating more rosemary as a cure, the idea that a kitchen herb might inspire the next generation of brain treatments is both poetic and powerful.
What makes this approach different
Alzheimer’s drug discovery has had a rocky road. Many high-profile drugs targeting beta-amyloid plaques or tau proteins have failed in clinical trials, largely because they were tested on people whose disease had already progressed too far. What Lipton’s team is doing is very different.
By focusing on the earliest changes—how neurons behave before visible damage sets in—they’re opening the door to prevention. This also allows for a much more targeted search for treatments. The 50 proteins identified through this method aren’t just statistically interesting—they’re functionally connected to how the neurons are firing.
One of the biggest advantages is the specificity. Lipton’s team hopes this will lead to better “target engagement” in clinical trials—meaning drugs will interact with the right molecules in the right cells at the right time. As Lipton put it, “We’re not just fishing in the dark anymore.”
What’s next in the search for treatment
According to the published study, the next phase will involve testing carnosic acid and related compounds in both organoids (lab-grown brain tissue) and animal models. This step is crucial before any human trials can begin. But the researchers are hopeful.
Lipton’s lab has a track record of identifying early drivers of neurological disease and translating them into therapies. His previous work contributed to the development of meantime, one of the few FDA-approved drugs for Alzheimer’s. Looking forward, the team also sees potential applications beyond Alzheimer’s. The same kind of single-cell analysis could be used for epilepsy, ALS, Parkinson’s and other conditions involving faulty neural activity.
A note of caution—and care
There’s one more aspect to consider here. While this research is a technical triumph and may pave the way for better treatments, it’s important to remember that Alzheimer’s, and cognitive disability more broadly, isn’t a problem to be “solved.” People with Alzheimer’s are not broken—and many disability advocates have called for more ethical nuance in the way research is discussed.
Saying that we might eventually “correct” certain forms of hyperactivity in brain cells is different from saying people with cognitive differences are less worthy. The goal here isn’t erasure—it’s care, support, and giving people options. That context matters, and it should stay central in how we talk about breakthroughs like this.
Still, in a field where so many efforts have faltered, this study gives researchers new tools, new ideas—and a renewed sense of possibility. From a single neuron’s signal to a compound found in rosemary, the path forward is finally becoming a little clearer.